Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma

Next Previous
Trial Profile

A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SynKIR 110 (Primary)
  • Indications Cholangiocarcinoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms STAR-101
  • Sponsors Verismo Therapeutics

Most Recent Events

  • 23 May 2025 According to Verismo Therapeutics media release, company provided additional details on the Trials in Progress poster presentation at the upcoming 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, being held from May 30 - June 3, 2025 in Chicago, IL.
  • 24 Apr 2025 According to Verismo Therapeutics media release, company to present trial in progress data from this study at the American Society of Clinical Oncology (ASCO), being held from May 30-June 3, 2025 in Chicago, IL.
  • 19 Aug 2024 Timeframe of primary endpoint changed from upto 36 months to upto 12 months

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top